

Ref: FOI/GS/ID 4659

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone  
Kent  
ME16 9QQ  
Email: mtw-tr.foiadmin@nhs.net

05 July 2018

**Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Non-Small Cell Lung Cancer.

*You asked:*

*Please provide the following information relating to NSCLC patients treated by your Trust in the 3 months, December 2017 to February 2018 inclusive.*

*If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.*

*1. Total number treated Stage IIIB/IV NSCLC Patients*

*If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:*

*2. Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months December 2017 to February 2018 inclusive, with the following therapies.*

*Total number treated Stage IIIB/IV NSCLC Patients*

*If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:*

*Docetaxel (mono or combination therapy)*

*Atezolizumab (Tecentriq)*

*Nivolumab (Opdivo)*

*Pembrolizumab (Keytruda)*

*3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:*

Trust response:

1.

Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:
---	---

Patients with NSCLC Stage IIIB/IV (Stage 3b/4) <sup>1</sup>	28	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	

2.

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:	
Docetaxel (mono or combination therapy )	0	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)	0	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Nivolumab (Opdivo)	0	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Pembrolizumab (Keytruda)	10	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	

3. Not applicable

---